youtube
The SITC 2025 session, “From Spatial Biology to Clinical Utility: Advancing Lung Cancer Diagnostics,” explores cutting-edge advancements in spatial biology technologies and their transformative potential in improving lung cancer diagnosis and treatment strategies. The discussion features insights from Dr. Carlo Bifulco, Chief Medical Officer at Providence Genomics and Director of Translational Molecular Pathology at EACRI, and Xiaoshan Wang, VP of Business Development for Spatomics, and , who share perspectives from both industry and clinical research.
Highlights:
• Emerging spatial biology tools enable high-resolution mapping of tumor microenvironments, revealing critical insights into lung cancer heterogeneity.
• Integration of multiplex imaging and AI-driven analytics enhances the identification of predictive biomarkers for personalized therapy.
• Translational research is bridging discoveries from the lab to clinical applications, supporting earlier and more accurate lung cancer detection.
• Collaborative efforts between academia, industry and diagnostics —including contributions from Wang and Bifulco—are accelerating the validation and adoption of spatial diagnostics.
---
Inquiry: (English) (Japanese)
|
